Young people with a rare condition called Juvenile Idiopathic Arthritis (JIA) are taking part in clinical research to better understand the condition, including to find out why some children have more ...

Methotrexate (MTX) is the widely agreed upon first-choice second-line agent to treat juvenile idiopathic arthritis (JIA), up to 75% of JIA patients in recent registries have used MTX at some time ...

The consensus based term for a rheumatic joint disorder in childhood is “juvenile idiopathic arthritis (JIA)”, and not “juvenile rheumatic coxitis.” [note: the author points out a mistake ...

Biologic therapy reduces TMJ inflammation in children with juvenile arthritis, according to a new study. Findings show ...

Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the ...